Objective. Describe the safety and long-term use of omalizumab in chronic urticaria (CU), both spontaneous (CSU) and inducible (CIndU ). Methods. Retrospective chart-review (2006-15) of CU patients treated with omalizumab for ≥ 6 months. Statistical analyses: descriptive statistics, Mann-Whitney, generalized linear models. Results. 23 patients with CSU (3 men), 3 with CIndU (2 men). Generalized linear models showed UAS reduction per omalizumab administration of 16% in CIndU and CSU (both p <

more »

... 01) and UAS7, of 15% in CIndU, and 20% in CSU (both p < 0.001). DLQI score at baseline had a median of 19 (CIndU and CSU) and after omalizumab a median of 0 (in both). Seven CSU patients stopped omalizumab and remain asymptomatic. No side-effects were observed. Conclusion. Omalizumab is safe and efficacious in CU. Stopping omalizumab can be tried, as some patients achieve remission. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal Abbreviations CU, chronic urticaria; CSU, chronic spontaneous urticaria; CIndU, chronic inducible urticaria; QoL, quality of life; CU-QoL, chronic urticaria quality of life; ASST, autologous serum skin test; DLQI, dermatology life quality index; UAS, urticaria activity score; nsAH, non-sedating H 1 -antihistamines